Related Experiment Video
Updated: Aug 21, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Targeted therapy for malignant gliomas
Andrew P Morokoff1, Ulrike Novak
1Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia. a_morokoff@hotmail.com
Abstract:
The identification of markers that are associated with tumour but not normal tissue has allowed the development of highly-specific targeted therapies. Monoclonal antibodies, either alone or linked to radioisotopes or toxins, have provided a powerful tool for research, as well as the basis for promising therapeutic agents with less side effects than standard radiotherapy or chemotherapy. A new class of drugs, the tyrosine kinase inhibitors, which interfere with the function of key molecules in cancer-promoting pathways, have had a dramatic effect in haematological malignancy and are being trialled in solid tumours, including glioma. Although the problem of achieving specific, high-level delivery of these various agents to tumours in the brain remains a major issue, encouraging early results with some targeted agents support the attractive theoretical principles of this new paradigm. Further work to identify new molecular targets and to develop agents exploiting them, is needed, as well as confirmation of their safety and efficacy by clinical trials.
Insights
Targeted therapies using monoclonal antibodies and tyrosine kinase inhibitors show promise for cancer treatment. Overcoming delivery challenges to brain tumors is key for realizing the potential of these novel agents.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Tumor-specific markers enable targeted therapies with fewer side effects than traditional treatments.
- Monoclonal antibodies and tyrosine kinase inhibitors represent advanced therapeutic strategies.
- Targeted agents offer a promising paradigm shift in cancer treatment.
Purpose of the Study:
- To review the development and potential of targeted therapies in oncology.
- To discuss the application of monoclonal antibodies and tyrosine kinase inhibitors.
- To highlight challenges and future directions in targeted cancer treatment.
Main Methods:
- Review of scientific literature on targeted cancer therapies.
- Analysis of the mechanisms of action for monoclonal antibodies and tyrosine kinase inhibitors.
- Discussion of clinical trial outcomes and challenges in drug delivery.
Main Results:
- Targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, demonstrate efficacy.
- Tyrosine kinase inhibitors have shown significant impact in hematological malignancies and are being tested in solid tumors.
- Early results for some targeted agents are encouraging, supporting their theoretical basis.
Conclusions:
- Targeted therapies offer a promising approach to cancer treatment with potentially reduced side effects.
- Further research is needed to identify new molecular targets and develop novel agents.
- Clinical trials are essential to confirm the safety and efficacy of these innovative treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy